Biosimilars – interchangeability/substitution and advertising

Many of the top selling drugs worldwide are biologics and many companies are seeking to produce biosimilars to compete in these lucrative markets.

Activity relating to biosimilars is intensifying in the US following the introduction of the BPCIA and continues in Europe since the first biosimilars were authorised in 2006. Successfully bringing a biosimilar to market raises different challenges to small molecule generics and there are differences in the approach in the US and Europe. 

Together with Willkie Farr & Gallagher, we're hosting a series of three webinars covering various aspects of market access for biosimilars. 

In our second webinar, we cover:

• access to market (how biosimilars are prescribed in the US, the UK, France, Germany and the Netherlands)
• issues relating to interchangeable biosimilars in the US
• advertising rules in the US compared to the position in UK, France, Germany and the Netherlands.